Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 7 | 2026 | 650 | 3.020 |
Why?
|
| Asthma | 9 | 2026 | 922 | 2.860 |
Why?
|
| Anti-Asthmatic Agents | 5 | 2026 | 133 | 1.910 |
Why?
|
| Bronchoscopy | 4 | 2019 | 178 | 1.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2026 | 570 | 1.060 |
Why?
|
| Patient Outcome Assessment | 2 | 2020 | 89 | 1.030 |
Why?
|
| Shock, Septic | 3 | 2025 | 150 | 0.980 |
Why?
|
| Bronchodilator Agents | 2 | 2026 | 158 | 0.970 |
Why?
|
| Lung | 4 | 2026 | 1535 | 0.920 |
Why?
|
| Noninvasive Ventilation | 3 | 2019 | 32 | 0.850 |
Why?
|
| Betacoronavirus | 3 | 2020 | 275 | 0.770 |
Why?
|
| Positive-Pressure Respiration | 2 | 2019 | 84 | 0.730 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 339 | 0.690 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 351 | 0.680 |
Why?
|
| Respiration, Artificial | 4 | 2020 | 501 | 0.670 |
Why?
|
| Smoking | 3 | 2022 | 932 | 0.670 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2020 | 18 | 0.640 |
Why?
|
| Eosinophils | 3 | 2026 | 122 | 0.630 |
Why?
|
| Symptom Flare Up | 1 | 2019 | 25 | 0.610 |
Why?
|
| Intensive Care Units | 4 | 2019 | 526 | 0.610 |
Why?
|
| Hepatitis B, Chronic | 1 | 2021 | 84 | 0.610 |
Why?
|
| Dengue | 1 | 2020 | 125 | 0.580 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 1882 | 0.580 |
Why?
|
| Fever | 2 | 2020 | 312 | 0.580 |
Why?
|
| Legionellosis | 1 | 2018 | 4 | 0.570 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2018 | 16 | 0.560 |
Why?
|
| Stroke | 3 | 2023 | 1061 | 0.540 |
Why?
|
| Glomerulonephritis | 1 | 2018 | 74 | 0.530 |
Why?
|
| Fungemia | 1 | 2017 | 22 | 0.530 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2018 | 104 | 0.510 |
Why?
|
| Lung Neoplasms | 3 | 2019 | 1545 | 0.510 |
Why?
|
| Humans | 37 | 2026 | 131163 | 0.490 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 182 | 0.490 |
Why?
|
| Candidiasis | 1 | 2017 | 134 | 0.480 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2016 | 22 | 0.470 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2016 | 37 | 0.470 |
Why?
|
| Inpatients | 1 | 2020 | 562 | 0.470 |
Why?
|
| Postoperative Hemorrhage | 1 | 2016 | 83 | 0.460 |
Why?
|
| Pulmonary Embolism | 1 | 2018 | 182 | 0.460 |
Why?
|
| HIV Infections | 2 | 2019 | 2049 | 0.460 |
Why?
|
| Pneumothorax | 1 | 2016 | 82 | 0.460 |
Why?
|
| Hemorrhage | 2 | 2020 | 487 | 0.460 |
Why?
|
| Hospital Mortality | 4 | 2025 | 1064 | 0.450 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 223 | 0.450 |
Why?
|
| Pulmonary Edema | 1 | 2015 | 54 | 0.450 |
Why?
|
| Esophagitis | 1 | 2015 | 46 | 0.450 |
Why?
|
| Shock, Hemorrhagic | 1 | 2015 | 50 | 0.440 |
Why?
|
| Acute Lung Injury | 1 | 2015 | 69 | 0.440 |
Why?
|
| Sarcoma, Kaposi | 1 | 2016 | 129 | 0.430 |
Why?
|
| Hepatic Encephalopathy | 1 | 2015 | 83 | 0.430 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2017 | 325 | 0.420 |
Why?
|
| Intracranial Thrombosis | 1 | 2014 | 12 | 0.420 |
Why?
|
| Streptococcus agalactiae | 1 | 2015 | 106 | 0.420 |
Why?
|
| Lung Diseases | 1 | 2018 | 398 | 0.410 |
Why?
|
| Factor VIIa | 1 | 2014 | 21 | 0.410 |
Why?
|
| Abscess | 1 | 2015 | 135 | 0.410 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 247 | 0.400 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 187 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 2596 | 0.400 |
Why?
|
| Fluid Therapy | 1 | 2014 | 141 | 0.400 |
Why?
|
| Hemophilia A | 1 | 2014 | 28 | 0.400 |
Why?
|
| Patient Admission | 3 | 2020 | 185 | 0.400 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 59 | 0.390 |
Why?
|
| Peptide Fragments | 1 | 2017 | 687 | 0.390 |
Why?
|
| Postoperative Complications | 2 | 2016 | 3147 | 0.390 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2014 | 58 | 0.390 |
Why?
|
| Hematoma | 1 | 2014 | 85 | 0.390 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 239 | 0.380 |
Why?
|
| Neck | 1 | 2014 | 140 | 0.380 |
Why?
|
| Aged | 15 | 2026 | 21025 | 0.380 |
Why?
|
| Biological Products | 2 | 2025 | 145 | 0.380 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 267 | 0.380 |
Why?
|
| Middle Aged | 15 | 2026 | 28601 | 0.370 |
Why?
|
| Male | 21 | 2026 | 64957 | 0.370 |
Why?
|
| Face | 1 | 2014 | 192 | 0.370 |
Why?
|
| Streptococcal Infections | 1 | 2015 | 254 | 0.370 |
Why?
|
| Resuscitation | 1 | 2014 | 258 | 0.360 |
Why?
|
| Disease Progression | 3 | 2026 | 2200 | 0.360 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 214 | 0.350 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2021 | 982 | 0.350 |
Why?
|
| Lymph Nodes | 1 | 2014 | 357 | 0.350 |
Why?
|
| Colitis, Ulcerative | 1 | 2014 | 211 | 0.350 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 457 | 0.350 |
Why?
|
| Coronary Artery Bypass | 1 | 2015 | 515 | 0.340 |
Why?
|
| Aged, 80 and over | 7 | 2026 | 6797 | 0.340 |
Why?
|
| Female | 21 | 2026 | 70963 | 0.320 |
Why?
|
| Sepsis | 1 | 2014 | 493 | 0.320 |
Why?
|
| Liver Neoplasms | 1 | 2021 | 1373 | 0.310 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2121 | 0.310 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2026 | 301 | 0.290 |
Why?
|
| Databases, Factual | 2 | 2026 | 1240 | 0.280 |
Why?
|
| Retrospective Studies | 10 | 2026 | 17753 | 0.270 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 903 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 750 | 0.270 |
Why?
|
| Biopsy | 3 | 2016 | 1239 | 0.260 |
Why?
|
| Severity of Illness Index | 3 | 2026 | 3061 | 0.250 |
Why?
|
| Drug Therapy, Combination | 2 | 2024 | 1173 | 0.240 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2026 | 56 | 0.240 |
Why?
|
| Cyclopropanes | 1 | 2026 | 70 | 0.240 |
Why?
|
| Aminopyridines | 1 | 2026 | 66 | 0.240 |
Why?
|
| Benzamides | 1 | 2026 | 127 | 0.230 |
Why?
|
| Smoking Cessation | 1 | 2026 | 191 | 0.220 |
Why?
|
| Biomarkers | 3 | 2026 | 3385 | 0.210 |
Why?
|
| Length of Stay | 3 | 2020 | 1421 | 0.210 |
Why?
|
| Phenotype | 3 | 2023 | 4497 | 0.210 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2026 | 333 | 0.210 |
Why?
|
| Safety-net Providers | 1 | 2025 | 93 | 0.200 |
Why?
|
| Molecular Targeted Therapy | 1 | 2026 | 386 | 0.200 |
Why?
|
| New York City | 2 | 2020 | 59 | 0.200 |
Why?
|
| Administration, Inhalation | 1 | 2024 | 193 | 0.200 |
Why?
|
| Doxycycline | 1 | 2023 | 112 | 0.190 |
Why?
|
| Sputum | 1 | 2023 | 113 | 0.190 |
Why?
|
| Biological Factors | 1 | 2022 | 25 | 0.190 |
Why?
|
| Respiratory System | 1 | 2022 | 94 | 0.180 |
Why?
|
| May-Thurner Syndrome | 1 | 2021 | 2 | 0.180 |
Why?
|
| Inflammation | 2 | 2023 | 1489 | 0.170 |
Why?
|
| Incidence | 2 | 2020 | 3360 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2025 | 282 | 0.170 |
Why?
|
| Adult | 8 | 2025 | 31282 | 0.170 |
Why?
|
| Neutrophils | 1 | 2023 | 371 | 0.170 |
Why?
|
| Prognosis | 3 | 2020 | 4886 | 0.160 |
Why?
|
| Gingiva | 1 | 2020 | 10 | 0.160 |
Why?
|
| Treatment Outcome | 4 | 2026 | 12936 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 164 | 0.150 |
Why?
|
| Thromboembolism | 1 | 2020 | 93 | 0.150 |
Why?
|
| Pulmonary Atelectasis | 1 | 2019 | 15 | 0.150 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1626 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 523 | 0.150 |
Why?
|
| Travel | 1 | 2020 | 117 | 0.150 |
Why?
|
| Conservative Treatment | 1 | 2019 | 46 | 0.150 |
Why?
|
| Pandemics | 3 | 2020 | 1118 | 0.150 |
Why?
|
| Legionella pneumophila | 1 | 2018 | 6 | 0.140 |
Why?
|
| Venous Thromboembolism | 2 | 2020 | 195 | 0.140 |
Why?
|
| Registries | 1 | 2026 | 1634 | 0.140 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2018 | 14 | 0.140 |
Why?
|
| Bronchiectasis | 1 | 2018 | 22 | 0.140 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2018 | 40 | 0.140 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 144 | 0.130 |
Why?
|
| Time Factors | 2 | 2026 | 6196 | 0.130 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 210 | 0.130 |
Why?
|
| Lipopeptides | 1 | 2017 | 37 | 0.130 |
Why?
|
| United States | 4 | 2026 | 12072 | 0.130 |
Why?
|
| Echinocandins | 1 | 2017 | 42 | 0.130 |
Why?
|
| Pulmonary Alveoli | 1 | 2018 | 139 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2020 | 1483 | 0.130 |
Why?
|
| Coinfection | 1 | 2018 | 187 | 0.120 |
Why?
|
| Computed Tomography Angiography | 1 | 2018 | 216 | 0.120 |
Why?
|
| Glioblastoma | 1 | 2020 | 371 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 2065 | 0.120 |
Why?
|
| Risk Factors | 3 | 2020 | 11074 | 0.120 |
Why?
|
| Thrombosis | 1 | 2020 | 499 | 0.110 |
Why?
|
| Anticoagulants | 1 | 2020 | 605 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 2304 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 1447 | 0.110 |
Why?
|
| Sternum | 1 | 2015 | 51 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2017 | 292 | 0.110 |
Why?
|
| Hospitalization | 2 | 2020 | 1950 | 0.110 |
Why?
|
| Certolizumab Pegol | 1 | 2014 | 7 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2017 | 825 | 0.110 |
Why?
|
| Antigens, Viral | 1 | 2016 | 395 | 0.110 |
Why?
|
| Tracheostomy | 1 | 2017 | 212 | 0.100 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 59 | 0.100 |
Why?
|
| Chest Pain | 1 | 2015 | 133 | 0.100 |
Why?
|
| Ecchymosis | 1 | 2014 | 11 | 0.100 |
Why?
|
| Facial Pain | 1 | 2014 | 9 | 0.100 |
Why?
|
| Mercaptopurine | 1 | 2014 | 72 | 0.100 |
Why?
|
| Mediastinum | 1 | 2014 | 44 | 0.100 |
Why?
|
| Prednisone | 1 | 2014 | 235 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 2085 | 0.100 |
Why?
|
| Radiography | 1 | 2015 | 743 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 1 | 2014 | 158 | 0.090 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 235 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 1306 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2015 | 943 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 82 | 0.080 |
Why?
|
| Echocardiography | 1 | 2016 | 1125 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 663 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1211 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2016 | 3359 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 3763 | 0.060 |
Why?
|
| Hospitals, Community | 2 | 2020 | 51 | 0.060 |
Why?
|
| Iliac Vein | 1 | 2021 | 24 | 0.040 |
Why?
|
| Femoral Vein | 1 | 2021 | 42 | 0.040 |
Why?
|
| Iliac Artery | 1 | 2021 | 63 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 38 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2020 | 59 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 97 | 0.040 |
Why?
|
| Comorbidity | 1 | 2025 | 1595 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 226 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 254 | 0.030 |
Why?
|
| Cytokines | 1 | 2024 | 1339 | 0.030 |
Why?
|
| Health Status | 1 | 2020 | 378 | 0.030 |
Why?
|
| Cerebellum | 1 | 2020 | 441 | 0.030 |
Why?
|
| Texas | 1 | 2025 | 3686 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2025 | 5063 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2825 | 0.030 |
Why?
|
| APACHE | 1 | 2011 | 55 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 3711 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 423 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 563 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 928 | 0.020 |
Why?
|
| Vitamin D | 1 | 2011 | 194 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 613 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2011 | 259 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1797 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1010 | 0.020 |
Why?
|